Chengdu Leadern Biotech's Subsidiary Receives Clinical Approval for Long-Acting Oligonucleotide Drug LDR2402 to Treat Hypertension

Recently, LDR2402 Injection, a self-developed drug by Leaderna Therapeutics Ltd. (hereinafter referred to as "Leaderna"), has been approved by the National Medical Products Administration (NMPA) of China for clinical trials. The first subject has been enrolled at the Sichuan Provincial People's Hospital, marking the beginning of a Phase I clinical study in China for a new generation of drugs to treat primary hypertension. Hypertension is one of the most common chronic diseases. The latest epidemiological survey shows that the prevalence of hypertension among adult residents in China is 27.9%. Despite the availability of various antihypertensive drugs in clinical practice, the control rate is only 16.8%, mainly due to poor medication adherence, complex dosing regimens, and other factors. LDR2402 Injection is a novel small nucleic acid drug developed based on RNA interference (RNAi) technology. It may improve patient compliance by extending the dosing interval (once every quarter or half a year) in clinical treatment. This drug has the potential to break through traditional bottlenecks in hypertension treatment and enhance therapeutic outcomes.

Leaderna Therapeutics Deeply Integrates the Advantages of Leaderna and Yuandong Bio in Equipment, Technical Expertise, Research Talent, and Other Hardware and Software Resources to Empower the Company’s Operations and Development. The Goal is to Build a Leading CDMO Service Platform for Small Nucleic Acid Drugs in the Industry. Currently, Leaderna Therapeutics Can Flexibly and Efficiently Provide One-Stop Early R&D Services for Small Nucleic Acid Drugs, CMC and Formulation Development, Production of Small Nucleic Acid APIs from Hundreds of Grams to Kilograms, as Well as Full-Chain Services Including Aseptic Formulation Filling Lines for Early Clinical Trials, New Drug IND Applications, and Product Commercialization.